Pacira Pharmaceuticals (PCRX) PT Lowered to $40 at Barclays
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $26.63 +0.19%
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 22
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 22
Join SI Premium – FREE
Barclays analyst Balaji Prasad lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $40.00 (from $50.00) while maintaining a Overweight rating.
You May Also Be Interested In
- JPMorgan Downgrades Inpex Corp (1605:JP) to Neutral
- Zensho Holdings (7550:JP) PT Raised to JPY13,300 at JPMorgan
- JPMorgan Upgrades Cosmo Energy Holdings (5021:JP) to Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
